About us
Neurostatus provides services for international and national randomized controlled trials (RCTs), academic studies and clinical routine and research groups. These include:
Our Mission
To develop innovative solutions to improve the reliability of clinical data in neurological disorders.
Our Vision
To become the leading global provider of innovative solutions for the qualitative and quantitative assessment of clinical symptoms in neurological disorders
Our Mission
To develop innovative solutions to improve the reliability of clinical data in neurological disorders.
Our Vision
To become the leading global provider of innovative solutions for the qualitative and quantitative assessment of clinical symptoms in neurological disorders
Who We Are
We are a dedicated team combining expertise in neurology, digital technology, software validation and operations to provide a seamless service to clinical and academic trials, as well as to support clinical routine and research.
Based in Basel, Switzerland, as part of the University Hospital Basel, Neurostatus-UHB is the leading provider of expertise in the standardised neurological assessment of clinical symptoms in Multiple Sclerosis (MS), including NMSOD and MOGAT; as well as related neuro-immunological diseases and other neurological disorders such as Huntington’s Disease.
We also develop digital solutions for the capture, quantification and documentation of clinical symptoms and has expertise in software validation.
Neurostatus-UHB started life in the early 1990s as a dedicated MS research group within the University Hospital Basel led by Professor Ludwig Kappos, developing the Neurostatus-EDSS It has since become the “gold-standard” for phase III RCTs in MS, including most noteworthy for those trials that led to the approval of the currently used disease modifying treatments (DMTs).
In 2009, led by the current CEO, PD Dr. med. Marcus D’Souza, the digital, algorithm-based version of the Neurostatus-EDSS, the Neurostatus-eEDSS, was introduced.
Along with the COO, Evy Fricker, and their team, they are currently supporting more than 100 active MS and related disorders studies, more than 30 of which are using the digital eEDSS.
In November 2021, the initial research group was incorporated as a limited company wholly owned by the University Hospital Basel.
Neurostatus provides services for international and national randomized controlled trials (RCTs), academic studies and clinical routine and research groups
Meet the Team
Under the executive leadership of PD Dr. med Marcus D’Souza, the Neurostatus team is highly trained and experienced in training physicians in the use of the Neurostatus-EDSS, conducting research projects with different partners, licensing access for the Neurostatus-EDSS and materials, as well as developing and validating digital solutions.
